MA29966B1 - Traitement des tumeurs neuroendocrines - Google Patents

Traitement des tumeurs neuroendocrines

Info

Publication number
MA29966B1
MA29966B1 MA30950A MA30950A MA29966B1 MA 29966 B1 MA29966 B1 MA 29966B1 MA 30950 A MA30950 A MA 30950A MA 30950 A MA30950 A MA 30950A MA 29966 B1 MA29966 B1 MA 29966B1
Authority
MA
Morocco
Prior art keywords
treatment
neuroendocrine tumors
tumors
administration
possibly
Prior art date
Application number
MA30950A
Other languages
English (en)
Inventor
Peter Wayne Marks
David Lebwohl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37671355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29966(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0523658A external-priority patent/GB0523658D0/en
Priority claimed from GB0601082A external-priority patent/GB0601082D0/en
Priority claimed from GB0602747A external-priority patent/GB0602747D0/en
Priority claimed from GB0607942A external-priority patent/GB0607942D0/en
Priority claimed from GB0609272A external-priority patent/GB0609272D0/en
Priority claimed from GB0609912A external-priority patent/GB0609912D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29966B1 publication Critical patent/MA29966B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN PROCÉDÉ DE TRAITEMENT DES TUMEURS ENDOCRINES, QUI COMPREND L'ADMINISTRATION D'UN INHIBITEUR DE MTOR, ÉVENTUELLEMENT EN ASSOCIATION AVEC UN AUTRE MÉDICAMENT.
MA30950A 2005-11-21 2008-05-20 Traitement des tumeurs neuroendocrines MA29966B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0523658A GB0523658D0 (en) 2005-11-21 2005-11-21 Organic compounds
GB0601082A GB0601082D0 (en) 2006-01-19 2006-01-19 Organic Compounds
GB0602747A GB0602747D0 (en) 2006-02-10 2006-02-10 Organic compounds
GB0607942A GB0607942D0 (en) 2006-04-21 2006-04-21 Organic compounds
GB0609272A GB0609272D0 (en) 2006-05-10 2006-05-10 Organic compounds
GB0609912A GB0609912D0 (en) 2006-05-18 2006-05-18 Organic compounds
EP06120660 2006-09-14

Publications (1)

Publication Number Publication Date
MA29966B1 true MA29966B1 (fr) 2008-11-03

Family

ID=37671355

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30950A MA29966B1 (fr) 2005-11-21 2008-05-20 Traitement des tumeurs neuroendocrines

Country Status (22)

Country Link
US (3) US9006224B2 (fr)
EP (3) EP2275103B1 (fr)
JP (3) JP2009516671A (fr)
KR (2) KR20140012218A (fr)
CN (1) CN103446138A (fr)
AU (2) AU2006314444C1 (fr)
BR (1) BRPI0618808A2 (fr)
CA (2) CA2933875C (fr)
CY (1) CY1115299T1 (fr)
DK (1) DK2275103T3 (fr)
ES (1) ES2481671T3 (fr)
HK (1) HK1150746A1 (fr)
HR (1) HRP20140708T1 (fr)
IL (3) IL191475A (fr)
MA (1) MA29966B1 (fr)
NO (4) NO346575B1 (fr)
NZ (1) NZ568182A (fr)
PL (1) PL2275103T3 (fr)
PT (1) PT2275103E (fr)
RU (1) RU2487711C2 (fr)
SI (1) SI2275103T1 (fr)
WO (1) WO2007057457A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3351246T (lt) 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
KR20080109068A (ko) * 2006-04-05 2008-12-16 노파르티스 아게 암을 치료하기 위한 ｂｃｒ-ａｂｌ/ｃ-ｋｉｔ/ｐｄｇｆ-ｒ ｔｋ 억제제를 포함하는 조합물
MX2008012715A (es) 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
WO2009117669A2 (fr) 2008-03-21 2009-09-24 The University Of Chicago Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
US9057054B2 (en) 2009-06-25 2015-06-16 The Regents Of The University Of Michigan Antigen-specific long-term memory T-cells
TWI643857B (zh) 2010-03-10 2018-12-11 英塞特公司 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
EP3659599B1 (fr) 2011-10-19 2022-12-21 Signal Pharmaceuticals, LLC 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one pour l'utilisation dans le traitement du glioblastome multiforme
WO2014134240A1 (fr) * 2013-02-28 2014-09-04 Signal Pharmaceuticals, Llc Traitement du cancer avec des inhibiteurs de la kinase tor
WO2014144405A1 (fr) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Utilisation d'inhibiteurs de mtor pour la prévention du développement et de la croissance d'une tumeur neuroendocrine
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
CA3206208A1 (fr) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Preparations orales de nanoparticules de rapamycine, et utilisation
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
WO2017000085A1 (fr) * 2015-06-30 2017-01-05 上海交通大学 Utilisation de sunlidac dans la préparation d'un produit de lutte contre le cancer du poumon
MA43800A (fr) * 2016-01-21 2021-05-12 Chiasma Inc Octréotide par voie orale pour le traitement de maladies
US11491247B2 (en) 2017-05-02 2022-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
US20210024542A1 (en) * 2018-02-09 2021-01-28 Torcept Therapeutics, Inc. Rapamycin analog for prevention and/or treatment of cancer
LT3788049T (lt) 2018-05-01 2023-07-25 Revolution Medicines, Inc. Rapamicino analogai, sujungti su c40-, c28- ir c32-, kaip mtor inhibitoriai
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
WO2020191002A1 (fr) * 2019-03-18 2020-09-24 The Regents Of The University Of California Compositions et procédés pour le traitement d'une maladie de cushing
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CA3220332A1 (fr) * 2021-06-07 2022-12-15 Nanopharmaceuticals Llc Composition et methode de double ciblage dans le traitement de tumeurs neuroendocrines
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
GB9013448D0 (en) 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
EP1110953B1 (fr) 1995-03-30 2009-10-28 Pfizer Products Inc. Dérivés de quinazolinone
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
IT1277391B1 (it) * 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
EP0896544B1 (fr) * 1996-06-11 2003-02-26 Novartis AG Association d'un analogue de somatostatine et d'une rapamycine
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
US5932613A (en) 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
EP0937082A2 (fr) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathog nes
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (fr) 1996-10-17 1998-04-22 Pfizer Inc. Dérivés de 4-aminoquinazoline
HU229833B1 (en) 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
NZ511722A (en) 1998-11-20 2004-05-28 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
IL143596A0 (en) 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
BR0009507A (pt) 1999-03-30 2002-01-15 Novartis Ag Derivados de ftalazina para o tratamento de doenças inflamatórias
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
RU2264405C2 (ru) 1999-12-06 2005-11-20 Новартис Аг 40-o-(2-гидрокси)этилрапамицин в кристаллической несольватированной форме, фармацевтическая композиция, содержащая такой макролид в качестве действующего вещества, и способ его получения
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ535616A (en) 2000-11-07 2006-03-31 Novartis Ag Indolymaleimide derivatives as protein kinase c inhibitors
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
LT3351246T (lt) * 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
KR100862178B1 (ko) * 2001-04-06 2008-10-09 와이어쓰 라파마이신과 겜시타빈 또는 플루오로우라실과의 항신생물제 배합물
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
CA2447732A1 (fr) 2001-06-01 2002-12-12 Wyeth Combinaisons antineoplasiques
UA78706C2 (en) 2001-06-01 2007-04-25 Wyeth Corp Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
KR100956195B1 (ko) 2002-02-01 2010-05-06 어리어드 파마슈티칼스, 인코포레이티드 인 함유 화합물 및 이의 용도
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
HUP0500844A2 (en) 2002-12-09 2007-08-28 Univ Texas Methods for selectively inhibiting janus tyrosine kinase 3(jak3)
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
EP1709449A1 (fr) 2003-12-22 2006-10-11 Novartis AG Biomarqueurs pour la sensibilite de maladies proliferantes aux inhibiteurs mtor
PT1704145E (pt) 2004-01-12 2012-09-04 Ym Biosciences Australia Pty Inibidores de quinase seletivos
WO2005082411A1 (fr) * 2004-02-23 2005-09-09 Sugen, Inc. Methode de traitement d'une croissance cellulaire anormale au moyen d'inhibiteurs c-met et m-tor
MXPA06009550A (es) * 2004-02-23 2007-03-01 Novartis Ag P53 tipo natural como biomarcadores para el tratamiento con inhibidores de mtor en combinacion con un agente citotoxico.
EP1827437B1 (fr) * 2004-12-15 2011-11-02 Novartis AG Combinaisons d'agents therapeutiques pour le traitement du cancer
US20060160837A1 (en) 2004-12-29 2006-07-20 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1

Also Published As

Publication number Publication date
CA2933875C (fr) 2018-06-26
EP1954269A2 (fr) 2008-08-13
WO2007057457A3 (fr) 2008-01-10
PT2275103E (pt) 2014-07-24
DK2275103T3 (da) 2014-07-07
CY1115299T1 (el) 2017-01-04
US9006224B2 (en) 2015-04-14
WO2007057457A2 (fr) 2007-05-24
NO344288B1 (no) 2019-10-28
NO20161045A1 (no) 2008-08-12
CA2629245A1 (fr) 2007-05-24
NZ568182A (en) 2010-08-27
EP2022498A2 (fr) 2009-02-11
SI2275103T1 (sl) 2014-07-31
US20080255029A1 (en) 2008-10-16
KR20080071600A (ko) 2008-08-04
KR20140012218A (ko) 2014-01-29
US20170128425A1 (en) 2017-05-11
NO20220050A1 (no) 2008-08-12
EP2275103A2 (fr) 2011-01-19
NO20170956A1 (no) 2008-08-12
JP5833048B2 (ja) 2015-12-16
JP2015061868A (ja) 2015-04-02
HK1150746A1 (en) 2012-01-13
IL191475A (en) 2017-08-31
CA2629245C (fr) 2016-07-12
JP5963836B2 (ja) 2016-08-03
CN103446138A (zh) 2013-12-18
AU2010202866A1 (en) 2010-07-29
RU2008124827A (ru) 2009-12-27
NO346575B1 (no) 2022-10-17
HRP20140708T1 (hr) 2014-09-26
EP2022498A3 (fr) 2012-08-15
NO341023B1 (no) 2017-08-07
AU2006314444B2 (en) 2010-08-26
ES2481671T3 (es) 2014-07-31
US20150148294A1 (en) 2015-05-28
EP2275103B1 (fr) 2014-04-23
EP2275103A3 (fr) 2011-10-12
AU2006314444A1 (en) 2007-05-24
JP2013144706A (ja) 2013-07-25
BRPI0618808A2 (pt) 2011-09-13
NO20082683L (no) 2008-08-12
AU2006314444C1 (en) 2018-01-04
CA2933875A1 (fr) 2007-05-24
IL250697A0 (en) 2017-04-30
PL2275103T3 (pl) 2014-09-30
RU2487711C2 (ru) 2013-07-20
IL253698A0 (en) 2017-09-28
JP2009516671A (ja) 2009-04-23

Similar Documents

Publication Publication Date Title
MA29966B1 (fr) Traitement des tumeurs neuroendocrines
TW200738270A (en) Method of treating depression using a TNFα antibody
NL301089I2 (nl) imlifidase
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
TW200714283A (en) Method and composition for treating peripheral vascular diseases
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
ITMO20040191A1 (it) Macchina e metodo per il trattamento extracorporeo di sangue.
MXPA05013773A (es) Metodo para elaborar carboxialquilcelulosa.
WO2007087468A3 (fr) L'adiponectine pour le traitement de divers troubles
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
DE602005013320D1 (de) Carbonitrierter rostfreier martensitischer Einsatzstahl
WO2007053284A3 (fr) Methode de traitement d'un cancer du sein au moyen de 17-aag ou 17-ag ou d'un promedicament d'un de ceux-ci conjointement avec un inhibiteur her2
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
UA88655C2 (ru) S-миртазапин для лечения прилива крови
WO2008028963A3 (fr) Utilisation de calréticuline comme médicament pour le traitement d'une maladie telle que le cancer chez un mammifère
MX2007005526A (es) Tratamiento de mastitis con enrofloxacino.
HK1115528A1 (en) Combination of pyrimidylaminobenzamide compounds and imatinib for treating or preventing proliferative diseases
SE0301650D0 (sv) Novel compounds
MX2007009914A (es) Uso de agonistas selectivos para el receptor-beta de estrogeno para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion.
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
WO2007010013A3 (fr) Composes organiques
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
MXPA05009428A (es) Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
WO2007010012A3 (fr) Combinaison de composes organiques